TY - JOUR
T1 - Economic Burden of Renal Cell Carcinoma—Part I
T2 - An Updated Review
AU - Chien, Chun Ru
AU - Geynisman, Daniel M.
AU - Kim, Bumyang
AU - Xu, Ying
AU - Shih, Ya Chen Tina
N1 - Funding Information:
The authors thank Dr. Gary Deyter, technical writer from the Department of Health Services Research, The University of Texas MD Anderson Cancer Center, for his editorial contribution. The data (i.e. Excel file of all abstracts reviewed for this study) generated for the current study are available from the corresponding author upon reasonable request.
Funding Information:
Funding We acknowledge funding from the China Medical University Hospital (Chien: CRS-106-040) and the National Cancer Institute (Shih: R01 CA207216 and CCSG P30 CA016672).
Publisher Copyright:
© 2018, Springer Nature Switzerland AG.
PY - 2019/3/12
Y1 - 2019/3/12
N2 - Background: The economic burden of renal cell carcinoma (RCC) had been reported to be significant in a previous review published in 2011. Objective: The objective of this study was to perform an updated review by synthesizing economic studies related to the treatment of RCC that have been published since the previous review. Methods: We performed a literature search in PubMed, EMBASE, and the Cochrane Library, covering English-language studies published between June 2010 and August 2018. We categorized these articles by type of analyses [cost-effectiveness analysis (CEA), cost analysis, and cost of illness (COI)] and treatment setting (cancer status and treatment), discussed findings from these articles, and synthesized information from each article in summary tables. Results: We identified 52 studies from 2317 abstracts/titles deemed relevant from the initial search, including 21 CEA, 23 cost analysis, and 8 COI studies. For localized RCC, costs were found to be positively associated with the aggressiveness of the local treatment. For metastatic RCC (mRCC), pazopanib was reported to be cost effective in the first-line setting. We also found that the economic burden of RCC has increased over time. Conclusion: RCC continues to impose a substantial economic burden to the healthcare system. Despite the large number of treatment alternatives now available for advanced RCC, the cost effectiveness and budgetary impact of many new agents remain unknown and warrant greater attention in future research.
AB - Background: The economic burden of renal cell carcinoma (RCC) had been reported to be significant in a previous review published in 2011. Objective: The objective of this study was to perform an updated review by synthesizing economic studies related to the treatment of RCC that have been published since the previous review. Methods: We performed a literature search in PubMed, EMBASE, and the Cochrane Library, covering English-language studies published between June 2010 and August 2018. We categorized these articles by type of analyses [cost-effectiveness analysis (CEA), cost analysis, and cost of illness (COI)] and treatment setting (cancer status and treatment), discussed findings from these articles, and synthesized information from each article in summary tables. Results: We identified 52 studies from 2317 abstracts/titles deemed relevant from the initial search, including 21 CEA, 23 cost analysis, and 8 COI studies. For localized RCC, costs were found to be positively associated with the aggressiveness of the local treatment. For metastatic RCC (mRCC), pazopanib was reported to be cost effective in the first-line setting. We also found that the economic burden of RCC has increased over time. Conclusion: RCC continues to impose a substantial economic burden to the healthcare system. Despite the large number of treatment alternatives now available for advanced RCC, the cost effectiveness and budgetary impact of many new agents remain unknown and warrant greater attention in future research.
UR - http://www.scopus.com/inward/record.url?scp=85057172678&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057172678&partnerID=8YFLogxK
U2 - 10.1007/s40273-018-0746-y
DO - 10.1007/s40273-018-0746-y
M3 - Review article
C2 - 30467701
AN - SCOPUS:85057172678
SN - 1170-7690
VL - 37
SP - 301
EP - 331
JO - PharmacoEconomics
JF - PharmacoEconomics
IS - 3
ER -